New depression drug LV232 enters Mid-Stage trial

NCT ID NCT06828887

Recruiting now Symptom relief Sponsor: Vigonvita Life Sciences Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 2 trial tests LV232, a new capsule for major depressive disorder, in 400 adults aged 18-65. Participants are randomly assigned to receive one of two doses of LV232, the active comparator escitalopram, or a placebo for 8 weeks. The main goal is to find the best dose and see if LV232 safely reduces depression symptoms, measured by changes in the MADRS score.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: LV232 capsules
What this could lead to: If successful, this could point toward a new treatment option for major depressive disorder, potentially offering an alternative for people who don't respond well to current antidepressants.
What could go wrong: This is an early Phase 2 dose-finding study, so it's not yet proven to work. The drug may not show significant benefit over placebo, and side effects are still being evaluated.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MAJOR DEPRESSIVE DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

endogenous depression major depressive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MDD

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Shanghai Mental Health Center Ethics Committee
RECRUITING

Shanghai, China

Contact Phone: •••-•••-••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.